In-vitro activity of cefepime/enmetazobactam against extended spectrum beta-lactamases and/or ampC producing Enterobacterales and Pseudomonas aeruginosa collected across India
Authors:
- 4 July 2025
- journal article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 113 (3) , 116993
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative InfectionsClinical Infectious Diseases, 2024
- Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolatesJournal of Global Antimicrobial Resistance, 2024
- Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute PyelonephritisJAMA, 2022
- Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against EnterobacteralesClinical Infectious Diseases, 2022
- Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016–2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactamJournal of Global Antimicrobial Resistance, 2021
- Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO StudyClinical Infectious Diseases, 2020
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients WithE coliorKlebsiella pneumoniaeBloodstream Infection and Ceftriaxone ResistanceJAMA, 2018
- Resistance surveillance program report for selected European nations (2011)Diagnostic Microbiology and Infectious Disease, 2014
- Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: A matched case–control studyJournal of Microbiology, Immunology and Infection, 2011
- Cefepime pharmacodynamics in patients with extended spectrum β-lactamase (ESBL) and non-ESBL infectionsJournal of Infection, 2007